TICKERNERD
Menu
SPTXHealthcare · Biotechnology

SPTX Stock Forecast: Seaport Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$21
−1.97% on the day

The 7 Wall Street analysts covering Seaport Therapeutics, Inc. hold a median 12-month price target of $35 — +63.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 19 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.1B
Ticker Nerd rank
1 / 100
Median analyst target
$35
Analysts covering
7
Total return, dividends reinvested
1W
−8.4%
1M
−10.8%
From high
−23.2%
From low
+40.3%
$15
$28
Range since 1 May 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

SPTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Seaport Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
43
Revisions
41
Issuance
11
Value
9
Growth
8
Accruals
8
Momentum
6
Quality
4
Volatility
4

Size (43): Smaller than most of the companies we track.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SPTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SPTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 1 May 2026Adjusted close, US dollars
$10$20$30$40$50May 26Jun 26Jul 26Aug 26Sep 26SPTXHigh $50Median $35Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $30Median $35High $50

The green dot is the last close — the median target sits +63.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Sept 2026HC Wainwright & Co.ReiteratesBuy$50
26 Aug 2026Jones TradingInitiatesBuy—
26 Aug 2026Jones TradingInitiatesBuy$32
20 Aug 2026HC Wainwright & Co.ReiteratesBuy—
20 Aug 2026HC Wainwright & Co.ReiteratesBuy$50
4 Aug 2026HC Wainwright & Co.ReiteratesBuy—
4 Aug 2026HC Wainwright & Co.ReiteratesBuy$50
15 July 2026HC Wainwright & Co.InitiatesBuy—
15 July 2026HC Wainwright & Co.InitiatesBuy$50
26 May 2026CitigroupInitiatesBuy$35
26 May 2026CitigroupInitiatesBuy—
26 May 2026JP MorganInitiatesOverweight$42
26 May 2026JP MorganInitiatesOverweight—
26 May 2026Leerink PartnersInitiatesOutperform—
26 May 2026Leerink PartnersInitiatesOutperform$35
26 May 2026StifelInitiatesBuy$30
26 May 2026StifelInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SPTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SPTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

SPTX vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140May 26Jun 26Jul 26Aug 26Sep 26SPTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SPTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Seaport Therapeutics, Inc. (SPTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.0×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
2.7×

Cheaper than 34% of US stocks

EV / EBITDA
−6.1×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
80.9%

Higher than 95% of US stocks

Return on assets
−30.1%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Seaport Therapeutics, Inc. (SPTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Seaport Therapeutics, Inc. has a market value of $1.1B and an enterprise value of $876.7M.

  • Shares outstanding: 53.0M.

  • Trailing P/E: −11.0×; forward P/E: −8.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Seaport Therapeutics, Inc. employs 58 people.

market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

SPTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SPTXSeaport Therapeutics, Inc.$1.1B
1
ODTXOdyssey Therapeutics, Inc.$1.2B
0
OBXObsidian Therapeutics, Inc.$1.1B
63
ANROAlto Neuroscience, Inc.$1.2B
56
MNKDMannKind Corp.$1.1B
34
JBIOJade Biosciences, Inc.$1.1B
24
APMDApnimed, Inc.$1.2B
1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Seaport Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SPTX news & analysis

Seaport Therapeutics to Participate in September Investor Conferences

Business Wire · 14 Sept 2026neutral

Seaport Therapeutics announced that members of its management team, including Co-Founder and CEO Daphne Zohar, will participate in additional investor conferences in September, featuring a company presentation and a panel discussion at the Goldman Sachs Life Sciences Sympo.

Why it matters — SPTX watchers would care because the company is increasing its investor visibility through management presentations and panel participation at a major industry conference.

Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 9 Sept 2026neutral

Seaport Therapeutics, Inc. (SPTX) presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. The item reports the company's participation in the summit event.

Why it matters — A SPTX watcher would care because the presentation provides a public forum for the company to communicate its biopharmaceutical activities to investors and industry attendees.

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

Business Wire · 9 Sept 2026positive

Seaport Therapeutics, a PureTech founded entity, reported positive topline results from its Phase 1 driving simulation trial of GlyphAllo in healthy volunteers. The results were announced via Business Wire.

Why it matters — A favorable Phase 1 driving simulation outcome for GlyphAllo is an early-stage development milestone that SPTX watchers would follow for the candidate's progress.

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

Business Wire · 9 Sept 2026positive

Seaport Therapeutics reported positive topline results from a Phase 1 driving simulation trial of GlyphAllo™ in healthy volunteers, as announced via Business Wire.

Why it matters — A SPTX watcher would care because positive Phase 1 results for GlyphAllo™ in a driving simulation trial may inform the candidate's safety profile and support its continued clinical development.

Seaport Therapeutics to Present at Citi's 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference

Business Wire · 31 Aug 2026neutral

Seaport Therapeutics announced that it will present at Citi's 2026 Biopharma Back to School Conference and participate in the 21st Annual Wells Fargo Healthcare Conference. The company made the announcement in a press release from Boston.

Why it matters — Seaport Therapeutics' presence at these major healthcare conferences gives investors and industry observers opportunities to hear directly from the company about its pipeline and developments.

FAQ

Frequently asked questions about SPTX stock

What is the SPTX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Seaport Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $30 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SPTX stock a buy right now?

Of the 7 analysts covering Seaport Therapeutics, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Seaport Therapeutics, Inc. 1 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SPTX?

As at 19 Sept 2026, Seaport Therapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (43 of 100).

Will SPTX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +63.6% from the last close, and Ticker Nerd's factor model ranks Seaport Therapeutics, Inc. 1 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SPTX stock forecast for 2030?

No analyst covering Seaport Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $50 over the next 12 months.

What does Seaport Therapeutics, Inc. do?

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing medicines for depression, anxiety, and other debilitating neuropsychiatric disorders.

What is the latest news on SPTX?

The most recent item we track (Business Wire, 14 Sept 2026): "Seaport Therapeutics to Participate in September Investor Conferences". Seaport Therapeutics announced that members of its management team, including Co-Founder and CEO Daphne Zohar, will participate in additional investor conferences in September, featuring a company presentation and a panel discussion at the Goldman Sachs Life Sciences Sympo.

Company

About Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing medicines for depression, anxiety, and other debilitating neuropsychiatric disorders. The company’s current pipeline is built around its proprietary Glyph platform, which is designed to advance orally administered therapies based on clinically validated mechanisms while improving delivery characteristics and reducing limitations associated with existing treatments. Its lead programs include GlyphAllo, an oral prodrug of allopregnanolone being developed for postpartum depression, and GlyphAgo, an oral prodrug of agomelatine being developed for anxiety and depression. Seaport Therapeutics works at the intersection of neuropsychiatry and drug development, targeting conditions with significant unmet medical need through a portfolio of product candidates intended for future clinical and commercial use. Headquartered in Boston, Massachusetts, Seaport Therapeutics is positioned as a specialized biopharmaceutical company with a focused approach to central nervous system therapeutics.

CEO Ms. Daphne Zohar · 58 employees · United States · https://www.seaporttx.com